Zelluna (ZLNA) BioStock Life Science Summit 2026 summary

Platform and differentiation

• TCR-NK combines T-cell receptors, which target cancer-associated patterns, with natural killer cells, which offer additional cancer-recognition mechanisms and a favorable clinical safety history.

• The dual-recognition approach is designed to improve solid-tumor targeting, scalability and resistance to tumor escape compared with single-target approaches.

• The platform has approved concept-patent coverage across major commercial territories, alongside IP on individual products and manufacturing.

Lead program and clinical progress

• Lead therapy ZI-MA4-1 targets MAGE-A4 and is being studied in lung, head and neck, ovarian cancers and sarcoma; patient treatment has begun, with dose escalation underway.

• The program is positioned as the only TCR-NK therapy targeting MAGE-A4; preclinical comparisons showed activity against mixed cancer-cell populations versus a TCR-T therapy targeting the same antigen.

• UK clinical sites are recruiting; the speaker cited FDA volatility as a factor in establishing the UK study.

• Responses in early patients could support registration-study potential and expand strategic options; pharmaceutical companies are watching for clinical data.

• A Q3 clinical progress update was scheduled for the following morning.

Market and development context

• Of nine cell-therapy approvals cited, seven were in liquid cancers and two in solid tumors; approval-enabling studies commonly included 44–97 patients.

• Iovance reported responses in 4 of 8 synovial sarcoma patients and moved toward a registration study, illustrating the potential value of small cell-therapy data sets.

• Recent multi-billion-dollar platform deals reflect industry demand for scalable cell therapies, though most programs cited target liquid cancers; solid tumors account for the larger cancer burden.

• The manufacturing process yields hundreds of vials per run, addressing a key cell-therapy scale-up challenge.